Retatrutide targets GIP, GLP-1, and glucagon receptors; semaglutide is a GLP-1 receptor agonist.
Open related pageComparison
retatrutide vs semaglutide
This is a status and evidence comparison, not a dose conversion, stacking guide, or substitute for medical advice.
Direct answer
Retatrutide is an investigational triple agonist. Semaglutide is a GLP-1 receptor agonist with FDA-approved prescription products for specific labeled uses.
Retatrutide is not FDA approved; semaglutide products have approved labels for specific uses.
Open related pageA clinician can discuss whether an approved semaglutide product is appropriate.
Open related pageWhat to know before acting on this search
- Lilly says retatrutide is currently in clinical trials and not available for public use.
- Approved semaglutide products still require a prescription, screening, label review, and monitoring.
- Retatrutide trial outcomes cannot be translated into semaglutide dosing or expectations.
- Weight-loss results vary by person, product, indication, adherence, and medical background.
Safety and compliance notes
- Do not stack retatrutide-like products with semaglutide without medical supervision.
- Do not use research-use retatrutide listings as substitutes for approved semaglutide care.
- Side effects and warnings should be interpreted through official labels and clinician review.
Safer next step
Use the GLP treatment comparison tool for status context, then take approved-treatment questions to a licensed clinician.
Medical disclaimer
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. FDA-approved medicines such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.